Accelerated Pharma (Accelerated Pharma) Equity-to-Asset : -35.31 (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Accelerated Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2017 was $-6.99 Mil. Accelerated Pharma's Total Assets for the quarter that ended in Mar. 2017 was $0.20 Mil.

The historical rank and industry rank for Accelerated Pharma's Equity-to-Asset or its related term are showing as below:

ACCP's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Accelerated Pharma Equity-to-Asset Historical Data

The historical data trend for Accelerated Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Equity-to-Asset Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Equity-to-Asset

-0.35

-5.78

-43.56

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Equity-to-Asset	Get a 7-Day Free Trial			-	-41.58	-27.20	-43.56	-35.31

Competitive Comparison of Accelerated Pharma's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Equity-to-Asset falls into.

Accelerated Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Accelerated Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Equity to Asset (A: Dec. 2016 )	=	Total Stockholders Equity	/	Total Assets
	=	-6.403	/	0.147
	=

Accelerated Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2017 is calculated as

Equity to Asset (Q: Mar. 2017 )	=	Total Stockholders Equity	/	Total Assets
	=	-6.991	/	0.198
	=

Accelerated Pharma (NAS:ACCP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Accelerated Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines